Biogen scraps two Alzheimer drug trials, wipes US$18 billion from market value

  • 📰 ChannelNewsAsia
  • ⏱ Reading Time:
  • 27 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 14%
  • Publisher: 66%

Business News News

Business Business Latest News,Business Business Headlines

Biogen and partner Eisai Co Ltd are ending two late-stage trials testing an Alzheimer's drug, they said Thursday, marking the latest setback for ...

CHICAGO/TOKYO: Biogen Inc and partner Eisai Co Ltd are ending two late-stage trials of their experimental Alzheimer's disease drug aducanumab, a major setback in the quest to find a treatment for the mind-wasting disease and blow to Biogen, which lost more than US$18 billion of its value on Thursday.

Markets in Japan were closed for a national holiday so the impact of the news on Eisai will be delayed. Abrahams, who reduced his Biogen price target to US$240 per share, said further declines were likely given that"investors owned Biogen to not miss out on what could have been one of the biggest blockbuster products in the pipeline of large biopharma."Any successful treatment for Alzheimer's, which affects about 5.7 million Americans, is virtually guaranteed to become one of the world's top-selling drugs.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 6. in BUSÄ°NESS

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Biogen scraps Alzheimer drug trials, wiping US$17 billion off its market valueBiogen and partner Eisai Co Ltd are ending two late-stage trials testing an Alzheimer's drug, they said Thursday, marking the latest setback for ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »

Biogen scraps Alzheimer drug trials, wiping US$17 billion off its market valueBiogen and partner Eisai Co Ltd are ending two late-stage trials testing an Alzheimer's drug, they said Thursday, marking the latest setback for ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »